Showcases open access initiatives supporting antimicrobial resistance efforts, including the AMR Studio podcast, BSAC’s educational and research resources, and REVIVE’s global platform for advancing antimicrobial R&D.

Featured presentations on global funding initiatives—CARB-X’s support for early-stage antibacterial innovation, JPI-AMR’s international collaborative funding for therapeutics and diagnostics, and GARDP’s nonprofit model for R&D and equitable access to treatments.

Presents the broad range of NIAID support mechanisms for infectious disease R&D—including grants, contracts, and research services—open to global applicants.

This course covers the basics on how to navigate the media landscape and the basics of popular science writing.

The AMR Knowledge Hub has links to many relevant resources, including those aimed at researchers developing therapeutics. It also has a regularly updated list of funding opportunities, fellowships and scholarships for AMR researchers. The Fleming Fund Knowledge Hub provides resources and training materials from projects that have received support from the Fleming Fund, organised by topic and region.

AMR.Solutions, curated by Dr John H. Rex, is a concise and authoritative platform offering expert‑curated newsletters, pipeline analyses, policy updates, incentive tracking, and open‑access tools to accelerate antimicrobial resistance research and development.

CC4CARB is an innovative chemistry centre focused on the synthesis and acquisition of rationally designed, focused compound libraries. It distributes these libraries free of charge to the global scientific community for use in Gram-negative antibacterial drug discovery programmes.

CARB-X (the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global, non-profit public-private partnership. It provides non-dilutive funding plus scientific, regulatory, business, and stewardship support to innovators.

INCATE—the INCubator for Antibacterial Therapies in Europe—supports the development of innovations addressing antimicrobial resistance. It provides targeted advice, funding and opportunities for community engagement.

ENABLE-2 is an Uppsala University-led, non-dilutive platform supporting early-stage antibacterial drug discovery and development. It combines expert mentorship with experimental capabilities in chemistry, microbiology, ADME, safety and in vivo efficacy to advance systemic antibiotic candidates targeting ESKAPE pathogens towards advanced lead status.

BEAM Alliance represents small and medium-sized companies developing AMR innovations, advocating for their interests and supporting policy, collaboration and sector visibility.

Provides evidence-based guidelines for diagnosing, treating and preventing infectious diseases, including resistant infections.

An interactive resource for exploring global AMR R&D investments across human, animal, plant and environmental sectors. It covers therapeutics, diagnostics, vaccines, surveillance and other interventions. It also presents pipelines for antibacterial therapeutics and bacterial vaccines, alongside incentives supporting antibacterial development and access.

ADVANCE-ID (Advancing Clinical Evidence in Infectious Diseases) is an international clinical research network generating evidence to improve the diagnosis, treatment and prevention of infections. Its work includes clinical trials, surveillance, observational studies, public engagement and research training.